Novartis AG (NVS)
| Market Cap | 278.65B +26.1% |
| Revenue (ttm) | 56.67B +9.6% |
| Net Income | 13.98B +17.1% |
| EPS | 7.15 +21.8% |
| Shares Out | 1.91B |
| PE Ratio | 19.89 |
| Forward PE | 16.43 |
| Dividend | $3.08 (2.11%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 2,019,732 |
| Open | 148.77 |
| Previous Close | 148.19 |
| Day's Range | 145.30 - 148.90 |
| 52-Week Range | 97.72 - 170.46 |
| Beta | 0.50 |
| Analysts | Hold |
| Price Target | 118.00 (-19.19%) |
| Earnings Date | Apr 28, 2026 |
About NVS
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $118.0, which is a decrease of -19.19% from the latest price.
News
Novartis Agrees Up to $3 Billion Synnovation Breast Cancer Drug Deal
Novartis Agrees Up to $3 Billion Synnovation Breast Cancer Drug Deal
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potent...
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug
Novartis to acquire SNV4818 for $3 billion, targeting PIK3CA-mutated breast cancer with a potentially safer, precision-based approach. ... Full story available on Benzinga.com
Novartis (NVS) Acquires Innovative Cancer Therapy SNV4818 for $3 Billion
Novartis (NVS) Acquires Innovative Cancer Therapy SNV4818 for $3 Billion
Novartis (NVS) to Acquire Breast Cancer Drug from Synnovation for $3B
Novartis (NVS) to Acquire Breast Cancer Drug from Synnovation for $3B
Novartis Places $3 Billion Bet On Early Cancer Drug
Novartis Places $3 Billion Bet On Early Cancer Drug
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
SNV4818 is being evaluated in an early and mid-stage study for breast cancer and other advanced solid tumors, Novartis said.
Novartis to buy breast cancer drug candidate from Synnovation
Novartis said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development ach...
Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Kα Inhibitor Program
WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology ...
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a next-g...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Big drugmakers must face US overcharge claims on medications for low-income patients
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharging ...
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal
JNVST Class 6 Selection Test 2026: Admit Card Out, Download Link Here
JNVST Class 6 Admit Card 2026: Navodaya Vidyalaya Samiti (NVS) has released the Class 6 JNVST admit card for winter-bound schools. Parents and teachers can download the admit card through the direct l...
AVDE, SHEL, HSBC, NVS: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Avantis International Equity ETF (Symbol: AVDE) where we have detected...
Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients
FDA approves Novartis' Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options. ... Full story available on Benzinga.com
Novartis (NVS) Announces New Share Buyback Program
Novartis (NVS) Announces New Share Buyback Program
Novartis Gains FDA Approval For Cosentyx In Pediatric Hidradenitis Suppurativa
(RTTNews) - Novartis AG (NVS) announced that the U.S. FDA has approved Cosentyx for pediatric patients aged 12 and older with moderate to severe hidradenitis suppurativa. The decision makes Cosentyx t...
Novartis (NVS) Gains FDA Approval for Pediatric Hidradenitis Suppurativa Treatment
Novartis (NVS) Gains FDA Approval for Pediatric Hidradenitis Suppurativa Treatment
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Basel, March 13, 2026 – Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate t...
Novartis AG (NVS) Stock Price Down 3.66% on Mar 11
Novartis AG (NVS) Stock Price Down 3.66% on Mar 11
Market Outlook: Costco, Novartis and Devon among stock picks
Three stock ideas from a quantitative investing model including Costco, Novartis and Devon Energy as markets remain volatile.
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies ...
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Novartis (NVS) Shareholders Approve Key Resolutions at Annual Meeting
Novartis (NVS) Shareholders Approve Key Resolutions at Annual Meeting